Characterization and screening of IgG binding to the neonatal Fc receptor

References

• Reichert JM. Antibodies to watch in 2014. MAbs 2013; 6:5 - 14; PMID: 24284914
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013?. MAbs 2013; 5:1 - 4; http://dx.doi.org/10.4161/mabs.22976; PMID: 23254906
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 2012; 14:554 - 8; http://dx.doi.org/10.1208/s12248-012-9369-y; PMID: 22610647
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715 - 25; http://dx.doi.org/10.1038/nri2155; PMID: 17703228
   PubMed Web of Science ®Google Scholar
• Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000; 18:739 - 66; http://dx.doi.org/10.1146/annurev.immunol.18.1.739; PMID: 10837074
   PubMed Web of Science ®Google Scholar
• Kacskovics I, Cervenak J, Erdei A, Goldsby RA, Butler JE. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies. MAbs 2011; 3:431 - 9; http://dx.doi.org/10.4161/mabs.3.5.17023; PMID: 22048692
   PubMed Web of Science ®Google Scholar
• Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective-- FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27:343 - 8; http://dx.doi.org/10.1016/j.it.2006.05.004; PMID: 16731041
   PubMed Web of Science ®Google Scholar
• Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2006; 290:G352 - 60; http://dx.doi.org/10.1152/ajpgi.00286.2005; PMID: 16210471
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157 - 9; http://dx.doi.org/10.1038/nbt.1601; PMID: 20081867
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011; 3:422 - 30; http://dx.doi.org/10.4161/mabs.3.5.16983; PMID: 22048693
   PubMed Web of Science ®Google Scholar
• Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 1976; 71:666 - 9; http://dx.doi.org/10.1083/jcb.71.2.666; PMID: 11223
   PubMed Web of Science ®Google Scholar
• Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867 - 77; http://dx.doi.org/10.1016/S1097-2765(01)00230-1; PMID: 11336709
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372:379 - 83; http://dx.doi.org/10.1038/372379a0; PMID: 7969498
   PubMed Web of Science ®Google Scholar
• West AP Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 2000; 39:9698 - 708; http://dx.doi.org/10.1021/bi000749m; PMID: 10933786
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591 - 604; http://dx.doi.org/10.1074/jbc.M009483200; PMID: 11096108
   PubMed Web of Science ®Google Scholar
• Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999; 29:2819 - 25; http://dx.doi.org/10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6; PMID: 10508256
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 2006; 103:18709 - 14; http://dx.doi.org/10.1073/pnas.0606304103; PMID: 17116867
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551 - 9; http://dx.doi.org/10.1093/intimm/13.12.1551; PMID: 11717196
   PubMed Web of Science ®Google Scholar
• Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods 2012; 375:20 - 9; http://dx.doi.org/10.1016/j.jim.2011.09.002; PMID: 21939661
   PubMed Web of Science ®Google Scholar
• Zhou J, Mateos F, Ober RJ, Ward ES. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol 2005; 345:1071 - 81; http://dx.doi.org/10.1016/j.jmb.2004.11.014; PMID: 15644205
   PubMed Web of Science ®Google Scholar
• Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor (FcRn) show dramatic differences in immunoglobulin G (IgG) and albumin binding. J Biol Chem 2010; 285:4826 - 36; http://dx.doi.org/10.1074/jbc.M109.081828
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 2013; 5:1 - 9; http://dx.doi.org/10.4161/mabs.23836; PMID: 23549129
   PubMed Web of Science ®Google Scholar
• Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469 - 77; http://dx.doi.org/10.1124/dmd.111.039453; PMID: 21610128
   PubMed Web of Science ®Google Scholar
• Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem 2012; 287:22927 - 37; http://dx.doi.org/10.1074/jbc.M112.355131; PMID: 22570488
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663 - 71; http://dx.doi.org/10.4049/jimmunol.0804182; PMID: 19494290
   PubMed Web of Science ®Google Scholar
• Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 1999; 38:12639 - 47; http://dx.doi.org/10.1021/bi9913505; PMID: 10504233
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385 - 92; http://dx.doi.org/10.1093/protein/gzq009; PMID: 20159773
   PubMed Web of Science ®Google Scholar
• Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I. A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods 2008; 331:39 - 49; http://dx.doi.org/10.1016/j.jim.2007.11.003; PMID: 18155020
   PubMed Web of Science ®Google Scholar
• Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, et al. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132 - 41; http://dx.doi.org/10.1016/j.jim.2010.12.014; PMID: 21185301
   PubMed Web of Science ®Google Scholar
• Kelley RF, Meng YG. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol Biol 2012; 901:277 - 93; http://dx.doi.org/10.1007/978-1-61779-931-0_18; PMID: 22723108
   PubMedGoogle Scholar
• Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346 - 56; PMID: 16365427
   PubMed Web of Science ®Google Scholar
• Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. J Immunol Methods 2013; 390:81 - 91; http://dx.doi.org/10.1016/j.jim.2013.01.011; PMID: 23384837
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 2009; 46:1878 - 82; http://dx.doi.org/10.1016/j.molimm.2009.02.002; PMID: 19269032
   PubMed Web of Science ®Google Scholar
• Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2:599; http://dx.doi.org/10.1038/ncomms1608; PMID: 22186895
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171 - 80; PMID: 12391234
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514 - 24; http://dx.doi.org/10.1074/jbc.M604292200; PMID: 16793771
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:86 - 94; http://dx.doi.org/10.1124/dmd.106.011734; PMID: 17050651
   PubMed Web of Science ®Google Scholar
• Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460 - 70; http://dx.doi.org/10.1016/j.coi.2008.06.012; PMID: 18656541
   PubMed Web of Science ®Google Scholar
• Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600 - 5; http://dx.doi.org/10.1124/dmd.109.031310; PMID: 20071453
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13:1 - 110; PMID: 4186070
   PubMedGoogle Scholar
• Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010; 29:48 - 52; http://dx.doi.org/10.1016/j.sder.2010.02.001; PMID: 20430307
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968 - 76; http://dx.doi.org/10.4049/jimmunol.0903296; PMID: 20083659
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282:1709 - 17; http://dx.doi.org/10.1074/jbc.M607161200; PMID: 17135257
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203 - 7; http://dx.doi.org/10.1038/nbt.1691; PMID: 20953198
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3:243 - 52; http://dx.doi.org/10.4161/mabs.3.3.15234; PMID: 21406966
   PubMed Web of Science ®Google Scholar
• Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 2013; 5:1 - 26; http://dx.doi.org/10.4161/mabs.24218; PMID: 23571156
   PubMed Web of Science ®Google Scholar
• Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem 2008; 377:209 - 17; http://dx.doi.org/10.1016/j.ab.2008.03.035; PMID: 18405656
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011; 48:860 - 6; http://dx.doi.org/10.1016/j.molimm.2010.12.009; PMID: 21256596
   PubMed Web of Science ®Google Scholar
• Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL Jr.. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008; 47:5088 - 100; http://dx.doi.org/10.1021/bi702238b; PMID: 18407665
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol 2006; 36:3044 - 51; http://dx.doi.org/10.1002/eji.200636556; PMID: 17048273
   PubMed Web of Science ®Google Scholar
• Gurbaxani BM, Morrison SL. Development of new models for the analysis of Fc-FcRn interactions. Mol Immunol 2006; 43:1379 - 89; http://dx.doi.org/10.1016/j.molimm.2005.08.002; PMID: 16183124
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283 - 8; http://dx.doi.org/10.1038/nbt1143; PMID: 16186811
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40:1545 - 55; http://dx.doi.org/10.1124/dmd.112.045864; PMID: 22584253
   PubMed Web of Science ®Google Scholar
• Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753 - 60; http://dx.doi.org/10.4161/mabs.22189; PMID: 23778268
   PubMed Web of Science ®Google Scholar
• Van den Brulle J, Fischer M, Langmann T, Horn G, Waldmann T, Arnold S, Fuhrmann M, Schatz O, O’Connell T, O’Connell D, et al. A novel solid phase technology for high-throughput gene synthesis. Biotechniques 2008; 45:340 - 3; http://dx.doi.org/10.2144/000112953; PMID: 18778261
   PubMed Web of Science ®Google Scholar
• Rothe C, Urlinger S, Löhning C, Prassler J, Stark Y, Jäger U, Hubner B, Bardroff M, Pradel I, Boss M, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008; 376:1182 - 200; http://dx.doi.org/10.1016/j.jmb.2007.12.018; PMID: 18191144
   PubMed Web of Science ®Google Scholar
• Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1 - 8; http://dx.doi.org/10.1016/S0161-5890(01)00050-5; PMID: 11483205
   PubMed Web of Science ®Google Scholar
• Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57 - 86; http://dx.doi.org/10.1006/jmbi.1999.3444; PMID: 10656818
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285 - 9; http://dx.doi.org/10.1073/pnas.89.10.4285; PMID: 1350088
   PubMed Web of Science ®Google Scholar
• Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531 - 53; http://dx.doi.org/10.1016/S0022-2836(02)01237-8; PMID: 12498801
   PubMed Web of Science ®Google Scholar
• Cho MS, Yee H, Chan S. Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci 2002; 9:631 - 8; http://dx.doi.org/10.1007/BF02254991; PMID: 12432229
   PubMed Web of Science ®Google Scholar